|
Immunotherapy in Treating Patients With Metastatic Breast Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Immunotherapy in Treating Patients With Metastatic Breast Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Immunotherapy in Treating Patients With Metastatic Breast Cancer Clinical research trials and Immunotherapy in Treating Patients With Metastatic Breast Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Immunotherapy in Treating Patients With Metastatic Breast Cancer. Immunotherapy in Treating Patients With Metastatic Breast Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Immunotherapy in Treating Patients With Metastatic Breast Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Immunotherapy in Treating Patients With Metastatic Breast Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immunotherapy in Treating Patients With Metastatic Breast Cancer  Immunotherapy in Treating Patients With Metastatic Breast Cancer
Immunotherapy in Treating Patients With Metastatic Breast Cancer
For Condition: stage 4 breast cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Duke Comprehensive Cancer Center
Synopsis: RATIONALE: Immunotherapy using CEA -treated white blood cells may help a person's body build an immune response to and kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with metastatic breast cancer who have achieved a partial or complete response after chemotherapy and peripheral stem cell transplantation.
Details: OBJECTIVES: I. Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant. II. Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population. PROTOCOL OUTLINE: Dendritic cells are taken from the leukapheresis product obtained during the peripheral blood stem cell transplant procedure performed prior to treatment on this study. The dendritic cells are pulsed with carcinoembryonic antigen (CEA) RNA. Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses. Patients undergo a second leukopheresis after the last dose of immunotherapy to obtain specimens for immunologic tests. Patients are followed every 3 months for the first year and annually thereafter. PROJECTED ACCRUAL: A total of 14-26 patients will be accrued for this study over 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed metastatic breast cancer that expresses carcinoembryonic antigen (CEA) - At least 25% of the tumor cells must stain positive for CEA with at least moderate intensity Must have achieved either partial response or complete response after high dose chemotherapy and peripheral blood stem cell transplant Hormone receptor status: Not specified --Prior/Concurrent Therapy-- Biologic therapy: - See Disease Characteristics - No concurrent immunotherapy Chemotherapy: - See Disease Characteristics - No concurrent chemotherapy Endocrine therapy: - At least 4 weeks since steroids - No concurrent steroid therapy Radiotherapy: No concurrent radiotherapy Surgery: Not specified Other: No concurrent immunosuppressive agents such as azathioprine or cyclosporine A --Patient Characteristics-- Age: 18 and over Menopausal status: Not specified Performance status: Karnofsky 70-100% Life expectancy: Greater than 6 months Hematopoietic: - Absolute neutrophil count at least 1000/mm3 - Absolute lymphocyte count at least 1000/mm3 - Hemoglobin at least 9 mg/dL - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin less than 2.0 mg/dL - No serious ongoing chronic or acute hepatic disease Renal: Creatinine less than 2.5 mg/dL Cardiovascular: No serious ongoing chronic or acute cardiac disease (New York Heart Association class III or IV) Pulmonary: No serious ongoing chronic or acute pulmonary illness such as asthma, chronic obstructive pulmonary disease, or radiation or drug induced pneumonitis Other: - No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years - No history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis - No inflammatory bowel condition such as active infectious enteritis or eosinophilic enteritis - No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis - Not pregnant or nursing
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HerbertLyerly, Study Chair, Duke Comprehensive Cancer Center
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Additional Information:
Study ID Numbers: CDR0000066458; DUMC-97148,NCI-G98-1455
Study Start Date: June 1998
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003432
Other Stage 4 Breast Cancer Studies:
1. Biological Therapy in Treating Women With Stage IV Breast Cancer
2. Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
3. Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
4. Combination Chemotherapy and Peripheral Stem Cell Transplantation Followed by Interleukin-2 and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
5. Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
Related Studies:
Other stage 4 breast cancer Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
Immunotherapy in Treating Patients With Metastatic Breast Cancer
|
|
|
|
|
|
|
|
